STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team..

康涅狄格州斯坦福德——（商业新闻短讯）——GeneDx（纳斯达克：WGS）是通过基因组洞察力改善健康结果的领导者，今天宣布任命Heidi Chen为首席法律官，自2024年11月25日起生效。海蒂将向首席执行官兼总裁凯瑟琳·斯图兰德（KatherineStueland）汇报工作，并担任行政领导团队成员。。

With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.

凭借30多年的经验，Heidi将领导GeneDx的所有法律、合规和政策职能，并将在公司治理、知识产权、监管事项、联邦政策、合规等方面提供战略咨询。

“With a massive transformation behind us and a clear runway for growth ahead, Heidi brings the expertise and leadership needed to guide GeneDx into this next chapter, particularly given the changing landscape in healthcare,” said Stueland. “Heidi is a celebrated and well-respected business leader and general counsel who brings extensive industry expertise to GeneDx.

斯图兰德说：“随着我们身后的巨大变革和未来增长的明确跑道，Heidi带来了必要的专业知识和领导力，可以指导GeneDx进入下一章，特别是考虑到医疗保健领域的不断变化。”。“Heidi是一位著名且备受尊敬的商业领袖和总顾问，为GeneDx带来了广泛的行业专业知识。

I’m happy to welcome Heidi to our executive leadership team to shape our business and legal strategy to advance critical initiatives to drive innovation as we enter this next phase of growth for our business.”.

我很高兴欢迎Heidi加入我们的高管领导团队，以制定我们的业务和法律战略，推动关键举措，从而在我们进入下一个业务增长阶段时推动创新。”。

Heidi joins GeneDx from Zoetis, where she served as General Counsel for nearly 12 years, a role she assumed following the company’s spinoff from Pfizer in 2013. During her tenure at Zoetis, she was instrumental in building the company’s legal department and establishing essential processes to support the company’s rapid growth.

Heidi从Zoetis加入GeneDx，在那里她担任了近12年的总法律顾问，这是2013年该公司从辉瑞（Pfizer）分拆后她担任的角色。在Zoetis任职期间，她在建立公司法律部门和建立支持公司快速发展的基本流程方面发挥了重要作用。

Heidi also oversaw global security, enterprise risk management, M&A, litigation and all corporate governance. In addition to her legal oversight, she also led operational strategy for a specialized human health diagnostics segment within the Zoetis business. Prior to the spinoff Heidi held a variety of leadership positions on Pfizer’s legal team and worked across compliance, litigation, licensing and risk management.

Heidi还负责全球安全、企业风险管理、并购、诉讼和所有公司治理。除了法律监督之外，她还领导了Zoetis业务中专门的人类健康诊断部门的运营战略。在分拆之前，Heidi在辉瑞的法律团队中担任过各种领导职位，并在合规、诉讼、许可和风险管理方面工作。

She began her career with roles at Hughes & Hubbard and Clifford Chance. Heidi holds a J.D. from Cornell Law School and a B.S. from Yale University..

她的职业生涯始于休斯哈伯德和克利福德机会。海蒂拥有康奈尔大学法学院的法学博士学位和耶鲁大学的学士学位。。

“I’m honored to have the opportunity to help accelerate GeneDx’s growth and continue transforming patient care,” said Chen. “I look forward to collaborating with the talented team at GeneDx to push boundaries, drive disruptive change, and pioneer innovations that deliver meaningful improvements in health outcomes.”.

陈说：“我很荣幸有机会帮助加速GeneDx的发展，并继续改变患者护理。”。“我期待着与GeneDx的天才团队合作，推动边界，推动颠覆性变革，开创创新，为健康结果带来有意义的改善。”。

About GeneDx:

关于GeneDx：

GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation services, fueled by the world’s largest, rare disease data sets.

GeneDx（纳斯达克：WGS）提供个性化和可行的健康见解，为诊断、直接治疗和改进药物发现提供信息。该公司在加速使用基因组和大规模临床信息以使精准医学成为护理标准方面具有独特的优势。GeneDx通过其业界领先的外显子组和基因组测试和解释服务，在世界上最大的罕见疾病数据集的推动下，处于医疗保健转型的前沿。

For more information, please visit www.genedx.com and connect with us on LinkedIn, Facebook, and Instagram..

有关更多信息，请访问www.genedx.com，并通过LinkedIn、Facebook和Instagram与我们联系。。